S 2507
Latest Information Update: 28 Jan 2011
At a glance
- Originator Galilaeus Oy
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Jan 2011 Discontinued - Preclinical for Cancer in Finland (unspecified route)
- 15 May 2003 S 2507 is available for licensing (http://www.galilaeus.fi)
- 15 May 2003 Preclinical trials in Cancer in Finland (unspecified route)